Patents by Inventor Olga Ignatovich
Olga Ignatovich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180142023Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.Type: ApplicationFiled: January 12, 2018Publication date: May 24, 2018Inventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
-
Patent number: 9908937Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.Type: GrantFiled: June 16, 2015Date of Patent: March 6, 2018Assignees: Bristol-Myers Squibb Company, Domantis LimitedInventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
-
Publication number: 20180051091Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: ApplicationFiled: August 3, 2017Publication date: February 22, 2018Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW
-
Patent number: 9765150Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: GrantFiled: November 24, 2015Date of Patent: September 19, 2017Assignees: Bristol-Myers Squibb Company, Domantis LimitedInventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
-
Publication number: 20160075790Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: ApplicationFiled: November 24, 2015Publication date: March 17, 2016Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW
-
Patent number: 9228018Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: GrantFiled: October 9, 2014Date of Patent: January 5, 2016Assignees: BRISTOL-MYERS SQUIBB COMPANY, DOMANTIS LIMITEDInventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
-
Publication number: 20150299321Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.Type: ApplicationFiled: June 16, 2015Publication date: October 22, 2015Inventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
-
Patent number: 9085629Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.Type: GrantFiled: March 9, 2012Date of Patent: July 21, 2015Assignees: BRISTOL-MYERS SQUIBB COMPANY, DOMANTIS LIMITEDInventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
-
Patent number: 8981072Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: GrantFiled: December 10, 2013Date of Patent: March 17, 2015Assignees: Bristol-Myers Squibb Company, Domantis LimitedInventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
-
Publication number: 20150023976Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: ApplicationFiled: October 9, 2014Publication date: January 22, 2015Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW
-
Patent number: 8895010Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: GrantFiled: October 12, 2012Date of Patent: November 25, 2014Assignees: Bristol-Myers Squibb Company, Domantis LimitedInventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
-
Publication number: 20140099707Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: ApplicationFiled: December 10, 2013Publication date: April 10, 2014Applicants: DOMANTIS LIMITED, BRISTOL-MYERS SQUIBB COMPANYInventors: Steven G. NADLER, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
-
Patent number: 8454959Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.Type: GrantFiled: March 9, 2012Date of Patent: June 4, 2013Assignees: Bristol-Meyers Squibb Company, Domantis LimitedInventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
-
Publication number: 20130109846Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.Type: ApplicationFiled: March 9, 2012Publication date: May 2, 2013Applicants: Domantis Ltd., Bristol-Myers Squibb CompanyInventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
-
Publication number: 20120201814Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.Type: ApplicationFiled: March 9, 2012Publication date: August 9, 2012Applicants: Domantis Ltd., Bristol-Myers Squibb CompanyInventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
-
Patent number: 8168759Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.Type: GrantFiled: July 17, 2009Date of Patent: May 1, 2012Assignees: Bristol-Myers Squibb Company, Domantis LimitedInventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
-
Publication number: 20110223168Abstract: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.Type: ApplicationFiled: May 19, 2011Publication date: September 15, 2011Inventors: Greg Winter, Ian Tomlinson, Olga Ignatovich, Lucy Holt, Elena De Angelis
-
Patent number: 7696320Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.Type: GrantFiled: January 11, 2006Date of Patent: April 13, 2010Assignee: Domantis LimitedInventors: Olga Ignatovich, Steve Holmes, Roland Beckmann, Rudolf M. T. de Wildt
-
Publication number: 20100081792Abstract: The invention provides a dual-specific ligand comprising a first and second single variable domain, each having binding specificity for a antigenic target. The invention also provides for a single variable domain monomer ligand that specifically binds to an antigenic target.Type: ApplicationFiled: October 31, 2007Publication date: April 1, 2010Applicant: SmithKline Beecham CorporationInventors: Steven Grant, Amrik Basran, Olga Ignatovich, Rudolph Maria T. De Wildt, Philip Jones, Neil Brewis, Ben Woolven, Elena De Angelis, Lucy J. Holt, Greg Winter, Ian Tomlinson, Kevin Moulder
-
Publication number: 20100056439Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.Type: ApplicationFiled: December 5, 2006Publication date: March 4, 2010Applicant: DOMANTIS LIMITEDInventors: Roland Beckmann, Rudolf M T De Wildt, Steve Holmes, Olga Ignatovich, Laurent S Jespers, Haiqun Liu, Malgorzata Pupecka, Armin Sepp, Michael Steward